Hoth Therapeutics (NASDAQ:HOTH) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $5.00 target price on the stock.

Several other research firms have also recently commented on HOTH. Wall Street Zen cut Hoth Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hoth Therapeutics has an average rating of “Hold” and a consensus target price of $5.00.

Hoth Therapeutics Price Performance

Shares of Hoth Therapeutics stock opened at $1.03 on Wednesday. The firm has a market cap of $15.98 million, a price-to-earnings ratio of -0.97 and a beta of 0.50. The stock’s 50-day moving average is $1.00 and its 200-day moving average is $1.24. Hoth Therapeutics has a one year low of $0.66 and a one year high of $2.12.

Institutional Trading of Hoth Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOTH. Lido Advisors LLC bought a new position in shares of Hoth Therapeutics in the 3rd quarter valued at about $32,000. Kestra Private Wealth Services LLC bought a new position in Hoth Therapeutics during the third quarter worth about $51,000. Geode Capital Management LLC increased its position in Hoth Therapeutics by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after buying an additional 9,071 shares during the last quarter. Virtu Financial LLC acquired a new position in Hoth Therapeutics during the third quarter worth approximately $184,000. Finally, Citadel Advisors LLC bought a new stake in Hoth Therapeutics in the third quarter valued at approximately $232,000. 7.08% of the stock is owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.